重磅:自我扩增mRNA(‘self-amplifying’ RNA/saRNA)抗新冠疫苗ARCT-154震撼上市!saRNA可在细胞内自我倍增,也就允许初始接种剂量很小,是常规mRNA疫苗的1/10-1/6,可降低副作用;越来越多研究证明,saRNA不仅用于呼吸道病毒感染预防,也能用于癌症防治;首个saRNA疫苗ARCT-154上周在日获完全授权,科学家20年
We evaluated two doses, 28 days apart, of ARCT-154, a self-amplifying mRNA COVID-19 vaccine, compared with saline placebo in an integrated phase 1/2/3a/3b controlled, observer-blind trial in Vietnamese adults (ClinicalTrial.gov identifier: NCT05012943). Primary safety and reactogenicity ...
Safety, tolerability and recommended phase 2 dose (RP2D) of an individualized, heterologous chimpanzee adenovirus (ChAd68) and self-amplifying mRNA (samRNA)-based neoantigen vaccine in combination with nivolumab and ipilimumab were assessed as primary endpoints in an ongoing phase 1/2 study in ...
mRNA is a genetic material that has been explored as an emerging bio-therapeutic agent in the form of vaccines, protein-replacement therapies, and gene therapies [[1], [2], [3]]. Though COVID-19 has led to the first clinical use for mRNA [[4], [5], [6]], it is now being exp...
Self-amplifying mRNA (samRNA) is rapidly emerging as a well-tolerated, scalable and widely-applicable platform technology which can be used to develop multiple vaccines simply by changing the sequence of the antigen (the target of t...
The analysis, entitled Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19 showed that GEMCOVAC-OM, administered exclusively with Tropis, generated high levels of ...
Rapid response to emerging diseases is critical when developing a vaccine. Long RNA (mRNA and saRNA) is at the forefront of vaccine development. Benefits of saRNA saRNA vaccines can be developed in a fraction of the time it takes to develop a conventional vaccine ...
Arcturus Therapeutics Holdings Inc. today shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19 disease caused by the SARS-CoV-2 virus.
Cells not expressing GFP had detectable but significantly lower levels of GFP mRNA, but there was no difference between low- and high-expressing cells, suggesting a role for the host response. When the transcriptomes between high and low expressor cells were compared, we observed differences in ...
and HIV-1. Self-amplifying RNAs have shown enhanced antigen expression at lower doses compared to conventional mRNA, suggesting this technology may improve immunization. This review will explore how self-amplifying RNAs are emerging as important vaccine candidates for infectious diseases, the advantages...